Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.58 USD
+0.01 (0.39%)
Updated May 22, 2024 04:00 PM ET
After-Market: $2.67 +0.09 (3.49%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARMP 2.58 +0.01(0.39%)
Will ARMP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates
Other News for ARMP
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial Moves
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
ARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Armata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic Advances